Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis (PR Newswire via Yahoo! Finance)
Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. Food and Drug Administration issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis.